Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peramivir Inhalation Solution for Uncomplicated Influenza
NCT07791251Phase 3Not yet recruiting
- Sponsor
- Capital Medical University
- Start
- Oct 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in influenza comparing Peramivir Inhalation Solution with Placebo (2 arms). Primary endpoint: Time to Alleviation of All Influenza Symptoms up to 336 hours. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
peramivir
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07791251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791251.